Support and Resistance Levels
Past performance
About Anthem Biosciences Ltd Anthem Biosciences Limited is a biotechnology and life sciences company that specializes in the manufacture of high-value products such as specialty organic molecules, biologically active peptides, and catalytic preparations. These are essential inputs for the pharmaceutical, agrochemical, and specialty chemicals industries. The company was initially established as Anthem Biosciences Private Limited in June 2006 and transitioned to a public company in December 2024, reflecting its trajectory of steady growth and strategic expansion.
Since commencing operations in 2007, Anthem Biosciences has consistently expanded its infrastructure and capabilities. It began with a small custom synthesis plant and discovery biology services and progressively scaled its operations. Notable milestones include the establishment of a high-potent lab in 2016, a GMP-compliant custom synthesis plant at Unit II with significant fermentation and synthesis capacity (128 KL and 80 KL, respectively) in 2018-19, and further expansion to a 246 KL capacity custom synthesis plant thereafter. Additionally, Anthem integrated Anthem Cellutions into its operations in 2017 to solidify its expertise and expand its technological capabilities. In FY 2024, the company diversified further by launching its wholly owned subsidiary, Neoanthem Lifesciences Private Limited, and beginning operations at Unit III to support ongoing and future projects.
The company is now planning an Initial Public Offering (IPO) to raise Rs. 3,395 crore through an Offer for Sale. This highlights its intent to broaden its public ownership and unlock value for stakeholders. Anthem Biosciences' operational growth and diversification, alongside its focus on innovation within the high-value biotech product space, make it a notable player within its industry—offering opportunities for investors seeking exposure to the life sciences and specialty chemicals sectors.